UB Paderborn / Katalog / Suche / in CDI

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Annals of oncology, 2014-10, Vol.25 (10), p.1871-1888

2014

Link zum Volltext

Verfügbarkeit prüfen

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Breast (Edinburgh), 2014-10, Vol.23 (5), p.489-502

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Journal of clinical oncology, 2005-08, Vol.23 (23), p.5305-5313

2005

Link zum Volltext

Verfügbarkeit prüfen

Erythropoietin Biology in Cancer

Clinical cancer research, 2006-01, Vol.12 (2), p.332-339

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-16-02: Variance between experts and community practitioners in treatment of metastatic breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-16-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-14-20: HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-14-20

2016

Link zum Volltext

Verfügbarkeit prüfen

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2502-2512

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-04-11: The foundation one assay influences clinical decision making in metastatic breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-04-11

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-08-12: HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-08-12

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-18

2018

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy

American journal of roentgenology (1976), 2003-11, Vol.181 (5), p.1275

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-22-16

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P4-P4-14-16

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-12-01: Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P1-P1-12-01

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.S4-S4-03

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-15-05: Novel targeted therapy for breast cancer chest wall recurrence: Low temperature liposomal doxorubicin and mild local hyperthermia

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-15-05

2013

Link zum Volltext

Verfügbarkeit prüfen

HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors

Clinical cancer research, 2004-06, Vol.10 (12), p.4083-4088

2004

Link zum Volltext

Verfügbarkeit prüfen

Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity

Molecular cancer therapeutics, 2006-02, Vol.5 (2), p.356-361

2006

Link zum Volltext

Verfügbarkeit prüfen

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis

British journal of cancer, 2005-12, Vol.93 (12), p.1350-1355

2005

Link zum Volltext

Verfügbarkeit prüfen

P1-13-03: Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P1-P1-13-03

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT1-1-11-OT1-1-11

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-05-02: Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(−) metastatic breast cancer (MBC) (TBCRC011)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P6-P6-05-02

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-14-01: Phosphatidylinositol 3-Kinase (PI3K) Pathway Activation in Breast Cancer Brain Metastases

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P1-P1-14-01

2010

Link zum Volltext

Verfügbarkeit prüfen

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P1-P1-17-01

2011

Link zum Volltext

Verfügbarkeit prüfen

Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin

Cancer research (Chicago, Ill.), 2003-10, Vol.63 (19), p.6162-6165

2003

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Erythropoietin Biology in Cancer

Abstract P5-16-02: Variance between experts and community practitioners in treatment of metastatic breast cancer

Abstract P1-14-20: HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Abstract P6-04-11: The foundation one assay influences clinical decision making in metastatic breast cancer

Abstract P5-08-12: HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015)

Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study

Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy

Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab

Abstract P1-12-01: Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC)

Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer

Abstract P4-15-05: Novel targeted therapy for breast cancer chest wall recurrence: Low temperature liposomal doxorubicin and mild local hyperthermia

HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors

Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis

P1-13-03: Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells

Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases

Abstract P6-05-02: Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(−) metastatic breast cancer (MBC) (TBCRC011)

Abstract P1-14-01: Phosphatidylinositol 3-Kinase (PI3K) Pathway Activation in Breast Cancer Brain Metastases

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial

Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin

Suchergebnisse filtern